← Back to Search

Anti-inflammatory

Camostat for Coronavirus

Phase 2
Waitlist Available
Led By Manisha Desai, PhD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Able and willing to understand the study, adhere to all study procedures, and provide written informed consent
Initial diagnosis of COVID-19 disease as defined by an FDA-cleared molecular diagnostic assay positive for SARS-CoV-2 with no more than 72 hours from the initial swab used in the diagnosis to the time of commencing informed consent.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights

Study Summary

This trial is designed to find new COVID-19 treatments that work for people who are infected but not yet sick enough to require hospitalization. The trial will test different therapies and adapt as new information becomes available.

Eligible Conditions
  • Coronavirus

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
For Clinical Domain: Time-to-sustained-resolution
For Viral Domain: Change in Viral Shedding
Secondary outcome measures
Number of Participants That Developed Antibodies to SARS-CoV-2
Number of Participants With SARS-CoV-2 Related Hospitalizations, Emergency Department (ED) Visits, or Death in Outpatients With COVID-19 Disease.
Time to First Resolution
+2 more

Side effects data

From 2023 Phase 2 & 3 trial • 4044 Patients • NCT04518410
10%
Blood glucose increased
6%
Blood creatinine increased
5%
Fatigue
4%
Alanine aminotransferase increased
3%
Dyspnoea
3%
Blood sodium decreased
3%
Pyrexia
3%
Cough
3%
Chills
3%
Hypertension
3%
Rhinorrhoea
3%
Nasal obstruction
2%
COVID-19 pneumonia
2%
Diarrhoea
2%
Pain
2%
Oropharyngeal pain
2%
Hyperglycaemia
2%
Diabetes mellitus
1%
Anaemia
1%
Back pain
1%
Infusion related reaction
1%
Headache
1%
Nausea
1%
Vomiting
1%
White blood cell count decreased
1%
Chest discomfort
1%
Hyperkalaemia
100%
80%
60%
40%
20%
0%
Study treatment Arm
SAB-185 (Low Dose) (Phase 3) OMICRON Population
Casirivimab and Imdevimab (Phase 3) OMICRON Population
AZD7442 (IM) (Phase 2)
BRII-196+BRII-198 (Pooled Phase 2/3)
Bamlanivimab 700mg (Phase 2)
Casirivimab and Imdevimab (Phase 3) Non-OMICRON Population
Bamlanivimab 700mg (Phase 3)
BRII-196+BRII-198 Placebo (Pooled Phase 2/3)
AZD7442 (IV) (Phase 2)
AZD7442 (IM) Pooled Placebo (Phase 2)
SNG001 (Phase 2)
Camostat (Phase 2)
SAB-185 (Low Dose) Pooled Placebo (Phase 2)
BMS 986414+BMS 986413 Pooled Placebo (Phase 2)
SAB-185 (Low Dose) (Phase 2)
SAB-185 (High Dose) Pooled Placebo (Phase 2)
BMS 986414+BMS 986413 (Phase 2)
AZD7442 (IV) Pooled Placebo (Phase 2)
Bamlanivimab 700mg Placebo (Phase 2)
Bamlanivimab 7000 mg (Phase 2)
Bamlanivimab 7000mg Placebo (Phase 2)
Camostat Pooled Placebo (Phase 2)
SAB-185 (High Dose) (Phase 2)
SNG001 Pooled Placebo (Phase 2)
SAB-185 (Low Dose) (Phase 3) Non-OMICRON Population

Trial Design

2Treatment groups
Experimental Treatment
Group I: CamostatExperimental Treatment1 Intervention
Participants are randomized to receive either active camostat or matching placebo for 10 days.
Group II: AcebilustatExperimental Treatment1 Intervention
Participants are randomized to receive either active acebilustat or matching placebo for 28 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Camostat
2021
Completed Phase 3
~4170
Acebilustat
2021
Completed Phase 2
~250

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,374 Previous Clinical Trials
17,332,805 Total Patients Enrolled
Manisha Desai, PhDPrincipal InvestigatorStanford University
1 Previous Clinical Trials
1,277 Total Patients Enrolled
Upinder Singh, MDPrincipal InvestigatorStanford University
1 Previous Clinical Trials
168 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals have signed up to participate in this research project?

"This study is not actively recruiting patients at this time. The study was initially posted on 4/23/2021 and was most recently edited on 9/12/2022. If you are searching for for other studies, there are currently 1137 studies actively searching for participants with covid19 and 4 studies for Camostat actively searching for participants."

Answered by AI

Are individuals over the age of 50 eligible to participate in this research project?

"Eligibility requirements for this study include being over 18 but under 80 years old."

Answered by AI

Has Camostat gone through the FDA's approval process?

"Camostat's safety was given a score of 2 out of 3 because, while there is data supporting its safety, Phase 2 trials have not yet yielded any efficacy data."

Answered by AI

Is this a new clinical trial?

"Currently, 4 clinical trials are running that involve Camostat. These studies span 11 countries and 177 cities. The first study began in 2020 and was sponsored by AstraZeneca. This initial trial had 4044 participants and completed Phase 2 & 3 of drug approval process. In the year since then, 12 more studies have been conducted."

Answered by AI

How can I sign-up for this opportunity?

"Eligible patients for this study must have contracted covid19 and be between 18-80 years old. So far, the trial has enrolled 122 individuals."

Answered by AI

Are we still able to register for this trial?

"This particular trial is not currently recruiting patients. However, it's important to note that the date of the last update was September 12th, 2022. There are 1137 other trials related to Covid-19 that are actively searching for participants and 4 trials for Camostat."

Answered by AI

What is the published research on Camostat's efficacy?

"Out of the 4 ongoing studies involving Camostat, 1 is currently in Phase 3. Most research surrounding Camostat takes place in Miami, yet there are 260 different clinical trial sites worldwide."

Answered by AI
~31 spots leftby Mar 2025